clobazam has been researched along with Absence Seizure in 84 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diazepam nasal spray (Valtoco), indicated for acute treatment of frequent seizure activity (seizure clusters) in patients with epilepsy ≥6 years of age, is designed to be a rapid, noninvasive, socially acceptable route of administration." | 9.41 | Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study. ( Biton, V; Carrazana, E; Cascino, GD; Cook, DF; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021) |
| "To determine long-term safety and efficacy of adjunctive clobazam for patients with Lennox-Gastaut syndrome (LGS)." | 9.19 | Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. ( Conry, JA; Drummond, R; Isojarvi, J; Kernitsky, L; Lee, D; Mitchell, WG; Ng, YT; Paolicchi, JM; Veidemanis, R, 2014) |
| "To determine the safety and efficacy (measured by the incidence of 'treatment failure') of clobazam in comparison to standard treatment with phenytoin-sodium for prevention of seizures in persons with solitary cysticercus granulomas (SCGs)." | 9.12 | Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. ( Chopra, SC; Kaushal, S; Rani, A; Singh, G, 2006) |
| "Clobazam, a novel benzodiazepine, was used as an add-on agent in 47 adult patients with intractable epilepsy and a variety of seizure types." | 9.06 | Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. ( Blaschuk, K; Couture, M; Guberman, A; Sherwin, A, 1990) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset focal or generalized seizures." | 8.98 | Clobazam monotherapy for focal or generalized seizures. ( Anand, V; Arya, R; Garg, SK; Giridharan, N, 2018) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset partial or generalized seizures." | 8.90 | Clobazam monotherapy for partial-onset or generalized-onset seizures. ( Anand, V; Arya, R; Garg, SK; Michael, BD, 2014) |
| "This retrospective chart review study (GWEP20052) evaluated plant-derived highly purified cannabidiol (CBD; Epidyolex®; 100 mg/mL oral solution) use without clobazam as add-on therapy in patients aged ≥2 years with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) enrolled in a European Early Access Program." | 8.31 | Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome. ( Arzimanoglou, A; Auvin, S; Berquin, P; Cross, JH; Desurkar, A; Fuller, D; Nabbout, R; Nortvedt, C; Pulitano, P; Rosati, A; Soto, V; Villanueva, V, 2023) |
| "To prospectively study the effectiveness and safety of clobazam as an add-on therapy in patients with epilepsy whose seizures are not adequately controlled with antiseizure medicine (ASM) monotherapy." | 8.12 | Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience. ( Agadi, J; Agarwal, VK; Alagesan, S; Apte, A; Arora, V; Asokan, K; Chauhan, D; Chodankar, D; Garg, S; Gurumukhani, J; Jha, SK; Kumar, A; Lingappa, L; Mandal, A; Menon, B; Padhy, U; Rathore, C; Ravat, S; Razdan, S; Satishchandra, P; Shah, SV; Shetty, S; Sundaracharya, NV; Venkateshwarlu, K; Vk, S, 2022) |
| " We review the use of short burst Clobazam dosing on discharge from the Epilepsy monitoring unit (EMU) to determine if this might reduce rates of representation with seizures." | 7.91 | Short burst Clobazam dosing at discharge from VEEG evaluation reduces re-presentation with seizures. ( Dionisio, S; Gillinder, L; Scarborough, L, 2019) |
| "This is a prospective study of children with Lennox-Gastaut syndrome receiving clobazam as adjunctive therapy." | 7.91 | Evaluation of the Effects of Clobazam on Seizure Control and Quality of Life in Children With Lennox-Gastaut Syndrome: A Pilot Study. ( Agarwal, N; Cheema, Z; Farooq, O; Hamilton, D; Parrish, J; Weinstock, A, 2019) |
| "A 12-year-old boy with intractable epilepsy had tonic and atonic seizures despite treatment with valproic acid (3000mg/day), levetiracetam (3000mg/day) and clobazam (40mg/day)." | 7.83 | Aggravation of atonic seizures by rufinamide: A case report. ( Aydın, A; Aydınlı, N; Bektaş, G; Çalışkan, M; Özmen, M; Pembegül Yıldız, E; Tatlı, B, 2016) |
| "Clobazam has been used in clinical practice as an adjunctive treatment for diverse seizure types and epilepsy syndromes." | 7.80 | Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. ( Bergin, AM; Bolton, J; Bourgeois, B; Harini, C; Kadish, NE; Klehm, J; Libenson, M; Loddenkemper, T; Peters, J; Poduri, A; Rotenberg, A; Sánchez Fernández, I; Takeoka, M; Thome-Souza, S, 2014) |
| "In addition to reducing convulsive seizure frequency, STP also markedly reduces the number of status epilepticus episodes and associated medical complications which are more common in younger children." | 7.01 | Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam. ( Vasquez, A; Wirrell, EC; Youssef, PE, 2023) |
| " The key outcomes were reduction in seizure frequency, differences in 50% responder rates, adverse events, and interactions with clobazam as co-therapy." | 7.01 | Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023) |
| "Here, one such patient became seizure free, allowing us to identify and compare the changes in hippocampal electrophysiology associated with ANT stimulation and seizure freedom." | 5.91 | Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023) |
| "The average number of seizures per month during the previous 3 months before CNB treatment was 19." | 5.91 | Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023) |
| "Several studies suggest antiseizure effects also beyond these three epilepsy syndromes." | 5.91 | Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. ( Bast, T; Becker, LL; Bertsche, A; Borggraefe, I; Boßelmann, CM; De Vries, H; Fahrbach, J; Hertzberg, C; Herz, NA; Hirsch, M; Holtkamp, M; Janello, C; Kaindl, AM; Klotz, KA; Kluger, GJ; Kühne, F; Kurlemann, G; Lerche, H; Makridis, KL; Prager, C; Pringsheim, M; Schubert-Bast, S; Schulz, J; Schulze-Bonhage, A; Steinbart, D; Steinhoff, BJ; Strzelczyk, A; Syrbe, S; von Podewils, F; Wagner, C; Wagner, J; Wilken, B, 2023) |
| "Clobazam is an effective agent to use as add-on AED in TRE, with 94% of patients showing a significant response within 6 months." | 5.62 | Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy. ( Bachman, E; Brahmbhatt, N; Bushara, O; Schuele, SU; Stupp, R; Templer, JW, 2021) |
| " In the absence of clinical trial data on optimization of AED dosage in patients with LGS, dose titration is guided by personal experience, anecdotal evidence, and specific patient factors (age, comorbid conditions and medications, seizure types, etc." | 5.48 | Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome. ( Chung, S; Gidal, BE; Isojarvi, J; Wechsler, RT, 2018) |
| "Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures." | 5.48 | Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018) |
| "Diazepam nasal spray (Valtoco), indicated for acute treatment of frequent seizure activity (seizure clusters) in patients with epilepsy ≥6 years of age, is designed to be a rapid, noninvasive, socially acceptable route of administration." | 5.41 | Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study. ( Biton, V; Carrazana, E; Cascino, GD; Cook, DF; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021) |
| "Each baseline seizure-frequency quartile had ~40 patients, and baseline weekly drop-seizure frequency ranges were as follows: <10 (Quartile 1), 10-30 (Quartile 2), 32-86 (Quartile 3), and 86-1077 (Quartile 4)." | 5.40 | Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience. ( Benbadis, SR; Drummond, R; Isojarvi, J; Lee, D; Wheless, JW, 2014) |
| " However, extensive animal studies followed by clinical trials are necessary to develop a product suitable for emergencies of acute seizures in status epilepticus and patients suffering from drug tolerance and hepatic impairment on long-term use in treatment of epilepsy, schizophrenia, and anxiety." | 5.37 | Intranasal clobazam delivery in the treatment of status epilepticus. ( Ambikanandan, M; Ankur, K; Florence, K; Kumar, BA; Kumar, MA; Manisha, L, 2011) |
| "These audiogenic-like seizures were blocked by clobazam microinjection into the substantia nigra (SN) and partially modified by SN vehicle injection." | 5.28 | Neuroethological evaluation of audiogenic seizures and audiogenic-like seizures induced by microinjection of bicuculline into the inferior colliculus. II. Effects of nigral clobazam microinjections. ( Garcia-Cairasco, N; Terra, VC, 1992) |
| "To determine long-term safety and efficacy of adjunctive clobazam for patients with Lennox-Gastaut syndrome (LGS)." | 5.19 | Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. ( Conry, JA; Drummond, R; Isojarvi, J; Kernitsky, L; Lee, D; Mitchell, WG; Ng, YT; Paolicchi, JM; Veidemanis, R, 2014) |
| "To determine the safety and efficacy (measured by the incidence of 'treatment failure') of clobazam in comparison to standard treatment with phenytoin-sodium for prevention of seizures in persons with solitary cysticercus granulomas (SCGs)." | 5.12 | Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. ( Chopra, SC; Kaushal, S; Rani, A; Singh, G, 2006) |
| "Clobazam, a novel benzodiazepine, was used as an add-on agent in 47 adult patients with intractable epilepsy and a variety of seizure types." | 5.06 | Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. ( Blaschuk, K; Couture, M; Guberman, A; Sherwin, A, 1990) |
| "To evaluate the potential impact of concomitant clobazam (CLB) use on the efficacy of cannabidiol (CBD) treatment in patients with Dravet syndrome and Lennox-Gastaut syndrome using meta-analytical techniques." | 5.05 | Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. ( Brigo, F; Del Giovane, C; Lattanzi, S; Nardone, R; Silvestrini, M; Striano, P; Trinka, E; Zaccara, G, 2020) |
| "Four pivotal randomized placebo-controlled trials have demonstrated that adjunctive therapy with cannabidiol (CBD) improves seizure control in patients with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS)." | 5.05 | Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. ( Bialer, M; Perucca, E, 2020) |
| "The efficacy of cannabidiol (CBD) with and without concomitant clobazam (CLB) was evaluated in stratified analyses of four large randomized controlled trials, two in Lennox-Gastaut syndrome, and two in Dravet syndrome." | 5.05 | Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials. ( Checketts, D; Devinsky, O; Dunayevich, E; Knappertz, V; Morrison, G; Thiele, EA; Wright, S, 2020) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset focal or generalized seizures." | 4.98 | Clobazam monotherapy for focal or generalized seizures. ( Anand, V; Arya, R; Garg, SK; Giridharan, N, 2018) |
| "To evaluate the efficacy, effectiveness, tolerability and safety of clobazam as monotherapy in people with new-onset partial or generalized seizures." | 4.90 | Clobazam monotherapy for partial-onset or generalized-onset seizures. ( Anand, V; Arya, R; Garg, SK; Michael, BD, 2014) |
| "This retrospective chart review study (GWEP20052) evaluated plant-derived highly purified cannabidiol (CBD; Epidyolex®; 100 mg/mL oral solution) use without clobazam as add-on therapy in patients aged ≥2 years with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) enrolled in a European Early Access Program." | 4.31 | Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome. ( Arzimanoglou, A; Auvin, S; Berquin, P; Cross, JH; Desurkar, A; Fuller, D; Nabbout, R; Nortvedt, C; Pulitano, P; Rosati, A; Soto, V; Villanueva, V, 2023) |
| " The mean baseline seizure frequency before initiation of clobazam was 2 (range 1-30) seizures per month." | 4.31 | Tolerability of clobazam as add-on therapy in patients aged 50 years and older with drug-resistant epilepsy. ( Bunch, ME; Frawley, B; Lynch, TM; Nagarajan, E, 2023) |
| "To prospectively study the effectiveness and safety of clobazam as an add-on therapy in patients with epilepsy whose seizures are not adequately controlled with antiseizure medicine (ASM) monotherapy." | 4.12 | Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience. ( Agadi, J; Agarwal, VK; Alagesan, S; Apte, A; Arora, V; Asokan, K; Chauhan, D; Chodankar, D; Garg, S; Gurumukhani, J; Jha, SK; Kumar, A; Lingappa, L; Mandal, A; Menon, B; Padhy, U; Rathore, C; Ravat, S; Razdan, S; Satishchandra, P; Shah, SV; Shetty, S; Sundaracharya, NV; Venkateshwarlu, K; Vk, S, 2022) |
| "Clobazam (CLB) is an effective anticonvulsant used as an adjunctive treatment for several seizures and epilepsy syndromes." | 4.12 | CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up. ( Öztürk, G; Türkdoğan, D, 2022) |
| "Cannabidiol (CBD) has been shown to reduce seizures among patients with refractory epilepsies of various etiologies in recent clinical trials and an expanded access program (EAP)." | 4.02 | The long-term efficacy of cannabidiol in the treatment of refractory epilepsy. ( Bruno, PL; Fleming, B; Grinspoon, R; Patel, S; Skirvin, LA; Thiele, EA; Wade, C; Wolper, E, 2021) |
| "With this study, we aim to test the hypothesis that the effect of cannabidiol on drop-seizure frequency in patients with Lennox-Gastaut syndrome and Dravet syndrome could be attributed to a drug-drug interaction with clobazam." | 3.96 | Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency. ( Bergmann, KR; Broekhuizen, K; Groeneveld, GJ, 2020) |
| "This is a prospective study of children with Lennox-Gastaut syndrome receiving clobazam as adjunctive therapy." | 3.91 | Evaluation of the Effects of Clobazam on Seizure Control and Quality of Life in Children With Lennox-Gastaut Syndrome: A Pilot Study. ( Agarwal, N; Cheema, Z; Farooq, O; Hamilton, D; Parrish, J; Weinstock, A, 2019) |
| "Clobazam is a commonly used long-acting benzodiazepine approved by the US Food and Drug Administration (FDA) to treat seizures associated with Lennox Gastaut syndrome." | 3.91 | Safety and Efficacy of Supratherapeutic Doses of Clobazam. ( Freedman, DA; Gedela, S; Glynn, P; Patel, AD; Salvator, A, 2019) |
| " We review the use of short burst Clobazam dosing on discharge from the Epilepsy monitoring unit (EMU) to determine if this might reduce rates of representation with seizures." | 3.91 | Short burst Clobazam dosing at discharge from VEEG evaluation reduces re-presentation with seizures. ( Dionisio, S; Gillinder, L; Scarborough, L, 2019) |
| "Clobazam treatment tailored to the timing of patient's seizures may improve seizure control." | 3.83 | Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsy. ( Fernández, IS; Jackson, M; Kadish, NE; Klehm, J; Loddenkemper, T; Manganaro, S; Thome-Souza, S, 2016) |
| "A 12-year-old boy with intractable epilepsy had tonic and atonic seizures despite treatment with valproic acid (3000mg/day), levetiracetam (3000mg/day) and clobazam (40mg/day)." | 3.83 | Aggravation of atonic seizures by rufinamide: A case report. ( Aydın, A; Aydınlı, N; Bektaş, G; Çalışkan, M; Özmen, M; Pembegül Yıldız, E; Tatlı, B, 2016) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| "Clobazam (CLB), a 1,5-benzodiazepine (BZD), was FDA-approved in October 2011 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older." | 3.80 | Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes. ( Ebert, B; Jensen, HS; Lee, D; Nichol, K, 2014) |
| "Clobazam has been used in clinical practice as an adjunctive treatment for diverse seizure types and epilepsy syndromes." | 3.80 | Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy. ( Bergin, AM; Bolton, J; Bourgeois, B; Harini, C; Kadish, NE; Klehm, J; Libenson, M; Loddenkemper, T; Peters, J; Poduri, A; Rotenberg, A; Sánchez Fernández, I; Takeoka, M; Thome-Souza, S, 2014) |
| "Stiripentol is an effective and well-tolerated therapy that markedly reduced frequency of prolonged seizures in Dravet syndrome." | 3.79 | Stiripentol in Dravet syndrome: results of a retrospective U.S. study. ( Chancharme, L; Chugani, H; de Menezes, MS; Devinsky, O; Franz, DN; Hamiwka, L; Hernandez, A; Laux, L; Le Guern, ME; Mikati, MA; Morse, RP; Saneto, RP; Sullivan, J; Valencia, I; Wirrell, EC, 2013) |
| " In one approach, mice were chronically treated with either diazepam, clonazepam, clobazam or the novel anxiolytic and anticonvulsant beta-carboline derivative abecarnil for 4 weeks, at doses which were about equipotent to increase the threshold for myoclonic seizures induced by pentylenetetrazole." | 3.69 | Long-term studies on anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. I. Comparison of diazepam, clonazepam, clobazam and abecarnil. ( Ebert, U; Hönack, D; Löscher, W; Rundfeldt, C, 1996) |
| "Tolerance to the anticonvulsant effects of clobazam has been studied in three murine models of epilepsy: pentylenetetrazole- and N-methyl-D,L-aspartic acid-induced seizures and audiogenic-induced seizures in the DBA/2 strain." | 3.68 | Tolerance to the anticonvulsant effects of clobazam in mice. ( Pleuvry, BJ; Wildin, JD, 1992) |
| "Preliminary studies of patients who had brain damage, intractable epilepsy, and mental subnormality showed that clobazam in small doses (20 to 30 mg/day) was beneficial, and indicated that a more detailed investigation was worthwhile." | 3.67 | On the anticonvulsant and psychotropic properties of clobazam--a preliminary study. ( Moffett, A; Scott, DF, 1986) |
| "Epidiolex® (CBD) is FDA-approved for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC)." | 3.30 | Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. ( Felton, E; Georgieva, D; Gidal, BE; Hartkopf, K; Hawk, L; Hsu, D; Langley, J; Margolis, A; Struck, A, 2023) |
| " The key outcomes were reduction in seizure frequency, differences in 50% responder rates, adverse events, and interactions with clobazam as co-therapy." | 3.01 | Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023) |
| "In addition to reducing convulsive seizure frequency, STP also markedly reduces the number of status epilepticus episodes and associated medical complications which are more common in younger children." | 3.01 | Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam. ( Vasquez, A; Wirrell, EC; Youssef, PE, 2023) |
| " ≥50% reduction in drop seizure frequency from baseline and occurrence of treatment-emergent adverse events (TEAEs) were the primary efficacy and safety outcomes." | 2.82 | Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis. ( Ameen, R; Bansal, D; Devi, N; Madaan, P; Sahu, JK, 2022) |
| "Clobazam (CLB) is a new antiepileptic drug that is the first 1,5-benzodiazepine (BZP) having nitrogen atoms in the 1 and 5 positions of the heterocyclic ring, whose chemical structure was designed to give it a different pharmacological profile from that of 1,4-BZPs." | 2.41 | [A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]. ( Nakajima, H, 2001) |
| "Several studies suggest antiseizure effects also beyond these three epilepsy syndromes." | 1.91 | Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study. ( Bast, T; Becker, LL; Bertsche, A; Borggraefe, I; Boßelmann, CM; De Vries, H; Fahrbach, J; Hertzberg, C; Herz, NA; Hirsch, M; Holtkamp, M; Janello, C; Kaindl, AM; Klotz, KA; Kluger, GJ; Kühne, F; Kurlemann, G; Lerche, H; Makridis, KL; Prager, C; Pringsheim, M; Schubert-Bast, S; Schulz, J; Schulze-Bonhage, A; Steinbart, D; Steinhoff, BJ; Strzelczyk, A; Syrbe, S; von Podewils, F; Wagner, C; Wagner, J; Wilken, B, 2023) |
| "Cenobamate is an antiseizure medication (ASM) approved for the treatment of partial-onset seizures in adults." | 1.91 | A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam. ( Bien, CG; Brandt, C; Elakkary, S; Hagemann, A; Klimpel, D, 2023) |
| " To support the use of cenobamate monotherapy, this pharmacokinetic (PK)-based simulation analysis evaluated the predicted PK exposure of cenobamate when used as monotherapy versus adjunctive therapy." | 1.91 | Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy. ( Ferrari, L; Kamin, M; Rosenfeld, WE; Vashi, V, 2023) |
| "The average number of seizures per month during the previous 3 months before CNB treatment was 19." | 1.91 | Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023) |
| "Here, one such patient became seizure free, allowing us to identify and compare the changes in hippocampal electrophysiology associated with ANT stimulation and seizure freedom." | 1.91 | Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023) |
| "A positive response (seizure-free and >50 % seizure reduction) was determined for focal-onset (62." | 1.72 | The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study. ( Arslan, EA; Aydın, K; Cansu, A; Çarman, KB; Dilber, B; Dündar, NO; Durgut, BD; Erdoğan, I; Gencpinar, P; Hız, SA; Kamaşak, T; Kılıç, BA; Okuyaz, Ç; Özen, N; Özkan Kart, P; Polat, BG; Şahin, S; Serdaroğlu, A; Serdaroğlu, E; Serin, HM; Tekgül, H; Topçu, Y; Yıldız, N; Yılmaz, Ö; Yücel Şen, AD, 2022) |
| " VPA showed a relatively short half-life in both mice and rats, which correlated with a sharp decline in efficacy." | 1.72 | Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach. ( Johnson, K; Mensah, JA; Metcalf, CS; Reilly, CA; Rower, JE; Wilcox, KS, 2022) |
| "Evidence for treating seizures in AS mainly derives from low-quality studies." | 1.72 | Pharmacotherapeutic management of seizures in patients with Angleman Syndrome. ( Samanta, D, 2022) |
| "Clobazam is an effective agent to use as add-on AED in TRE, with 94% of patients showing a significant response within 6 months." | 1.62 | Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy. ( Bachman, E; Brahmbhatt, N; Bushara, O; Schuele, SU; Stupp, R; Templer, JW, 2021) |
| "Mean reduction in weekly seizure frequency was greater at the best point of seizure control within the first year than at two months of treatment with CBD, regardless of concomitant CLB usage (all p > 0." | 1.56 | Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam. ( Anagnos, CJ; Bruno, PL; Savage, TE; Skirvin, LA; Sourbron, J; Thiele, EA; Wolper, ES, 2020) |
| "Seizures are present in over 90% of infants and children with Wolf-Hirschhorn syndrome (WHS)." | 1.48 | A survey of antiepileptic drug responses identifies drugs with potential efficacy for seizure control in Wolf-Hirschhorn syndrome. ( Battaglia, A; Carey, JC; Ho, KS; Lortz, A; Markham, LM; Newcomb, T; Olson, LM; Sheng, X; Twede, H; Wassman, ER; Weng, C, 2018) |
| "Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures." | 1.48 | Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018) |
| " In the absence of clinical trial data on optimization of AED dosage in patients with LGS, dose titration is guided by personal experience, anecdotal evidence, and specific patient factors (age, comorbid conditions and medications, seizure types, etc." | 1.48 | Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome. ( Chung, S; Gidal, BE; Isojarvi, J; Wechsler, RT, 2018) |
| "In addition, the effect on seizure count was compared with that of various AED regimen and the vagus nerve stimulation (VNS)." | 1.42 | Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen. ( Benninger, F; Dressler, A; Feucht, M; Grassl, R; Gröppel, G; Mühlebner, A; Reiter-Fink, E; Reithofer, E; Trimmel-Schwahofer, P, 2015) |
| "The seizures were easily controlled with valproate and clobazam." | 1.40 | Neck myoclonia with absence seizures in an Indian girl. ( Aneja, S; Jain, P; Sharma, S, 2014) |
| "The anticonvulsant interaction profile between 1-MeTHIQ and CLB in the mouse MES model was determined using an isobolographic analysis for parallel dose-response relationship curves." | 1.40 | Additive interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and clobazam in the mouse maximal electroshock-induced tonic seizure model--an isobolographic analysis for parallel dose-response relationship curves. ( Andres-Mach, M; Haratym-Maj, A; Luszczki, JJ; Zagaja, M, 2014) |
| "Each baseline seizure-frequency quartile had ~40 patients, and baseline weekly drop-seizure frequency ranges were as follows: <10 (Quartile 1), 10-30 (Quartile 2), 32-86 (Quartile 3), and 86-1077 (Quartile 4)." | 1.40 | Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience. ( Benbadis, SR; Drummond, R; Isojarvi, J; Lee, D; Wheless, JW, 2014) |
| " However, extensive animal studies followed by clinical trials are necessary to develop a product suitable for emergencies of acute seizures in status epilepticus and patients suffering from drug tolerance and hepatic impairment on long-term use in treatment of epilepsy, schizophrenia, and anxiety." | 1.37 | Intranasal clobazam delivery in the treatment of status epilepticus. ( Ambikanandan, M; Ankur, K; Florence, K; Kumar, BA; Kumar, MA; Manisha, L, 2011) |
| "The aim of this study was to characterize the anticonvulsant effects of stiripentol (STP) in combination with clobazam [CLB], and valproate [VPA]) in the mouse maximal electroshock (MES)-induced seizure model using the type I isobolographic analysis for parallel and non-parallel dose-response relationship curves (DRRCs)." | 1.36 | Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model. ( Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N; Trojnar, MK, 2010) |
| "Minimal, predominantly clonic seizures with preserved righting ability were reliably induced by pentylenetetrazol and suppressed by clobazam in rats aged 18 days or more." | 1.30 | Antipentylenetetrazol action of clobazam in developing rats. ( Haugvicová, R; Kubová, H; Mares, P, 1999) |
| "These audiogenic-like seizures were blocked by clobazam microinjection into the substantia nigra (SN) and partially modified by SN vehicle injection." | 1.28 | Neuroethological evaluation of audiogenic seizures and audiogenic-like seizures induced by microinjection of bicuculline into the inferior colliculus. II. Effects of nigral clobazam microinjections. ( Garcia-Cairasco, N; Terra, VC, 1992) |
| "The electrocardiogram showed a right bundle branch block and a left anterior hemiblock over 72 h." | 1.28 | [Maprotiline poisoning in an eleven-month-old infant]. ( Bétremieux, P; Breurec, JY; Dabadie, A; Durand, C; Lefrançois, C; Roussey, M, 1990) |
| "Three personal observations of "eating seizures' are described and similar cases in the literature considered." | 1.27 | Eating seizures. ( Aguglia, U; Tinuper, P, 1983) |
| "Maximal seizures were induced by electroshock (MES) and the chemical convulsants pentetrazol (PTZ), picrotoxin (PTX), bicuculline (BIC), isoniazid (INH), nicotine (NIC) and strychnine (STR)." | 1.27 | Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam. ( Kruse, HJ; Kuch, H, 1985) |
| "Tonic-clonic (maximal) seizures were induced by maximal electroshock (MES; 12 mA, 200 ms) and clonic (threshold) seizures by pentetrazol (PTZ; 85 mg/kg s." | 1.27 | Potentiation of clobazam's anticonvulsant activity by etifoxine, a non-benzodiazepine tranquilizer, in mice. Comparison studies with sodium valproate. ( Kruse, HJ; Kuch, H, 1986) |
| "Clobazam is a new benzodiazepine recently introduced in Canada on an experimental basis." | 1.27 | Clobazam for refractory childhood seizure disorders--a valuable supplementary drug. ( Camfield, C; Camfield, P; Dooley, J; Munn, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (8.33) | 18.7374 |
| 1990's | 13 (15.48) | 18.2507 |
| 2000's | 8 (9.52) | 29.6817 |
| 2010's | 31 (36.90) | 24.3611 |
| 2020's | 25 (29.76) | 2.80 |
| Authors | Studies |
|---|---|
| Yogeeswari, P | 1 |
| Sriram, D | 1 |
| Thirumurugan, R | 1 |
| Raghavendran, JV | 1 |
| Sudhan, K | 1 |
| Pavana, RK | 1 |
| Stables, J | 1 |
| Rajak, H | 1 |
| Singh Thakur, B | 1 |
| Singh, A | 1 |
| Raghuvanshi, K | 1 |
| Sah, AK | 1 |
| Veerasamy, R | 1 |
| Sharma, PC | 1 |
| Singh Pawar, R | 1 |
| Kharya, MD | 1 |
| Malik, S | 1 |
| Bahare, RS | 1 |
| Khan, SA | 1 |
| Satishchandra, P | 1 |
| Rathore, C | 1 |
| Apte, A | 1 |
| Kumar, A | 1 |
| Mandal, A | 1 |
| Chauhan, D | 1 |
| Agadi, J | 1 |
| Gurumukhani, J | 1 |
| Asokan, K | 1 |
| Venkateshwarlu, K | 1 |
| Lingappa, L | 1 |
| Sundaracharya, NV | 1 |
| Jha, SK | 1 |
| Ravat, S | 1 |
| Vk, S | 1 |
| Garg, S | 1 |
| Shah, SV | 1 |
| Alagesan, S | 1 |
| Razdan, S | 1 |
| Padhy, U | 1 |
| Agarwal, VK | 1 |
| Arora, V | 1 |
| Menon, B | 1 |
| Shetty, S | 1 |
| Chodankar, D | 1 |
| Devi, N | 1 |
| Madaan, P | 1 |
| Ameen, R | 1 |
| Sahu, JK | 1 |
| Bansal, D | 1 |
| Kamaşak, T | 1 |
| Serdaroğlu, E | 1 |
| Yılmaz, Ö | 1 |
| Kılıç, BA | 1 |
| Polat, BG | 1 |
| Erdoğan, I | 1 |
| Yücel Şen, AD | 1 |
| Özen, N | 1 |
| Durgut, BD | 1 |
| Yıldız, N | 1 |
| Özkan Kart, P | 1 |
| Dilber, B | 1 |
| Arslan, EA | 1 |
| Şahin, S | 1 |
| Topçu, Y | 1 |
| Gencpinar, P | 1 |
| Serin, HM | 1 |
| Hız, SA | 1 |
| Çarman, KB | 1 |
| Dündar, NO | 1 |
| Okuyaz, Ç | 1 |
| Aydın, K | 1 |
| Serdaroğlu, A | 1 |
| Tekgül, H | 1 |
| Cansu, A | 1 |
| Samanta, D | 1 |
| Mensah, JA | 1 |
| Johnson, K | 1 |
| Reilly, CA | 1 |
| Wilcox, KS | 1 |
| Rower, JE | 1 |
| Metcalf, CS | 1 |
| Talwar, A | 1 |
| Estes, E | 1 |
| Aparasu, R | 1 |
| Reddy, DS | 1 |
| Elakkary, S | 1 |
| Hagemann, A | 1 |
| Klimpel, D | 1 |
| Bien, CG | 1 |
| Brandt, C | 1 |
| Kühne, F | 1 |
| Becker, LL | 1 |
| Bast, T | 2 |
| Bertsche, A | 1 |
| Borggraefe, I | 1 |
| Boßelmann, CM | 1 |
| Fahrbach, J | 1 |
| Hertzberg, C | 1 |
| Herz, NA | 1 |
| Hirsch, M | 1 |
| Holtkamp, M | 1 |
| Janello, C | 1 |
| Kluger, GJ | 1 |
| Kurlemann, G | 2 |
| Lerche, H | 1 |
| Makridis, KL | 1 |
| von Podewils, F | 1 |
| Pringsheim, M | 1 |
| Schubert-Bast, S | 2 |
| Schulz, J | 1 |
| Schulze-Bonhage, A | 1 |
| Steinbart, D | 1 |
| Steinhoff, BJ | 1 |
| Strzelczyk, A | 2 |
| Syrbe, S | 1 |
| De Vries, H | 1 |
| Wagner, C | 1 |
| Wagner, J | 1 |
| Wilken, B | 1 |
| Prager, C | 1 |
| Klotz, KA | 1 |
| Kaindl, AM | 1 |
| Georgieva, D | 1 |
| Langley, J | 1 |
| Hartkopf, K | 1 |
| Hawk, L | 1 |
| Margolis, A | 1 |
| Struck, A | 1 |
| Felton, E | 1 |
| Hsu, D | 1 |
| Gidal, BE | 2 |
| Nagarajan, E | 1 |
| Lynch, TM | 1 |
| Frawley, B | 1 |
| Bunch, ME | 1 |
| Vasquez, A | 1 |
| Wirrell, EC | 2 |
| Youssef, PE | 1 |
| Nabbout, R | 1 |
| Arzimanoglou, A | 1 |
| Auvin, S | 1 |
| Berquin, P | 1 |
| Desurkar, A | 1 |
| Fuller, D | 1 |
| Nortvedt, C | 1 |
| Pulitano, P | 1 |
| Rosati, A | 1 |
| Soto, V | 1 |
| Villanueva, V | 1 |
| Cross, JH | 1 |
| Vashi, V | 1 |
| Rosenfeld, WE | 1 |
| Ferrari, L | 1 |
| Kamin, M | 1 |
| Serrano-Castro, PJ | 1 |
| Rodríguez-Uranga, JJ | 1 |
| Cabezudo-García, P | 1 |
| García-Martín, G | 1 |
| Romero-Godoy, J | 1 |
| Estivill-Torrús, G | 1 |
| Ciano-Petersen, NL | 1 |
| Oliver, B | 1 |
| Ortega-Pinazo, J | 1 |
| López-Moreno, Y | 1 |
| Aguilar-Castillo, MJ | 1 |
| Gutierrez-Cardo, AL | 1 |
| Ramírez-García, T | 1 |
| Sanchez-Godoy, L | 1 |
| Carreño, M | 1 |
| Skelton, HM | 1 |
| Brandman, DM | 1 |
| Bullinger, K | 1 |
| Isbaine, F | 1 |
| Gross, RE | 1 |
| Bergmann, KR | 1 |
| Broekhuizen, K | 1 |
| Groeneveld, GJ | 1 |
| Savage, TE | 1 |
| Sourbron, J | 1 |
| Bruno, PL | 2 |
| Skirvin, LA | 2 |
| Wolper, ES | 1 |
| Anagnos, CJ | 1 |
| Thiele, EA | 3 |
| Mandelbaum, DE | 1 |
| Lattanzi, S | 1 |
| Trinka, E | 1 |
| Striano, P | 1 |
| Zaccara, G | 1 |
| Del Giovane, C | 1 |
| Nardone, R | 1 |
| Silvestrini, M | 1 |
| Brigo, F | 1 |
| Bialer, M | 1 |
| Perucca, E | 1 |
| Devinsky, O | 2 |
| Wright, S | 1 |
| Checketts, D | 1 |
| Morrison, G | 1 |
| Dunayevich, E | 1 |
| Knappertz, V | 1 |
| Brahmbhatt, N | 1 |
| Stupp, R | 1 |
| Bushara, O | 1 |
| Bachman, E | 1 |
| Schuele, SU | 1 |
| Templer, JW | 1 |
| Türkdoğan, D | 1 |
| Öztürk, G | 1 |
| Segal, EB | 1 |
| Tarquinio, D | 1 |
| Miller, I | 1 |
| Wheless, JW | 2 |
| Dlugos, D | 1 |
| Biton, V | 1 |
| Cascino, GD | 1 |
| Desai, J | 1 |
| Hogan, RE | 1 |
| Liow, K | 1 |
| Sperling, MR | 1 |
| Vazquez, B | 1 |
| Cook, DF | 1 |
| Rabinowicz, AL | 1 |
| Carrazana, E | 1 |
| Patel, S | 1 |
| Grinspoon, R | 1 |
| Fleming, B | 1 |
| Wade, C | 1 |
| Wolper, E | 1 |
| Isojarvi, J | 3 |
| Chung, S | 1 |
| Wechsler, RT | 1 |
| Porcari, GS | 1 |
| Fu, C | 1 |
| Doll, ED | 1 |
| Carter, EG | 1 |
| Carson, RP | 1 |
| Ho, KS | 1 |
| Markham, LM | 1 |
| Twede, H | 1 |
| Lortz, A | 1 |
| Olson, LM | 1 |
| Sheng, X | 1 |
| Weng, C | 1 |
| Wassman, ER | 2 |
| Newcomb, T | 1 |
| Carey, JC | 1 |
| Battaglia, A | 1 |
| Arya, R | 2 |
| Giridharan, N | 1 |
| Anand, V | 2 |
| Garg, SK | 2 |
| Citraro, R | 1 |
| De Sarro, C | 1 |
| Leo, A | 1 |
| Donato di Paola, E | 1 |
| Palma, E | 1 |
| Russo, E | 1 |
| De Sarro, G | 1 |
| Gillinder, L | 1 |
| Scarborough, L | 1 |
| Dionisio, S | 1 |
| Weinstock, A | 1 |
| Agarwal, N | 1 |
| Farooq, O | 1 |
| Cheema, Z | 1 |
| Hamilton, D | 1 |
| Parrish, J | 1 |
| Gedela, S | 2 |
| Freedman, DA | 1 |
| Glynn, P | 1 |
| Salvator, A | 1 |
| Patel, AD | 1 |
| Wolff, M | 1 |
| Wiemer-Kruel, A | 1 |
| von Spiczak, S | 1 |
| Trollmann, R | 1 |
| Reif, PS | 1 |
| Pritchard, C | 1 |
| Polster, T | 1 |
| Neubauer, BA | 1 |
| Mayer, T | 1 |
| Macdonald, D | 1 |
| Kluger, G | 1 |
| Klein, KM | 1 |
| Kieslich, M | 1 |
| Kay, L | 1 |
| Kalski, M | 1 |
| Irwin, J | 1 |
| Herting, A | 1 |
| Carroll, J | 1 |
| Bettendorf, U | 1 |
| Rosenow, F | 1 |
| Besag, FMC | 1 |
| Vasey, MJ | 1 |
| Tayah, T | 1 |
| Savard, M | 1 |
| Desbiens, R | 1 |
| Nguyen, DK | 1 |
| Laux, L | 1 |
| Franz, DN | 1 |
| Sullivan, J | 1 |
| Saneto, RP | 1 |
| Morse, RP | 1 |
| Chugani, H | 1 |
| Hernandez, A | 1 |
| Hamiwka, L | 1 |
| Mikati, MA | 1 |
| Valencia, I | 1 |
| Le Guern, ME | 1 |
| Chancharme, L | 1 |
| de Menezes, MS | 1 |
| Jensen, HS | 1 |
| Nichol, K | 1 |
| Lee, D | 3 |
| Ebert, B | 1 |
| Jain, P | 1 |
| Sharma, S | 1 |
| Aneja, S | 1 |
| Conry, JA | 1 |
| Ng, YT | 1 |
| Kernitsky, L | 1 |
| Mitchell, WG | 1 |
| Veidemanis, R | 1 |
| Drummond, R | 2 |
| Paolicchi, JM | 1 |
| Klehm, J | 2 |
| Thome-Souza, S | 2 |
| Sánchez Fernández, I | 1 |
| Bergin, AM | 1 |
| Bolton, J | 1 |
| Harini, C | 1 |
| Kadish, NE | 2 |
| Libenson, M | 1 |
| Peters, J | 1 |
| Poduri, A | 1 |
| Rotenberg, A | 1 |
| Takeoka, M | 1 |
| Bourgeois, B | 2 |
| Loddenkemper, T | 2 |
| Andres-Mach, M | 1 |
| Haratym-Maj, A | 1 |
| Zagaja, M | 3 |
| Luszczki, JJ | 4 |
| Michael, BD | 1 |
| Benbadis, SR | 1 |
| Florek-Luszczki, M | 2 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Dressler, A | 1 |
| Trimmel-Schwahofer, P | 1 |
| Reithofer, E | 1 |
| Mühlebner, A | 1 |
| Gröppel, G | 1 |
| Reiter-Fink, E | 1 |
| Benninger, F | 1 |
| Grassl, R | 1 |
| Feucht, M | 1 |
| Bektaş, G | 1 |
| Çalışkan, M | 1 |
| Aydın, A | 1 |
| Pembegül Yıldız, E | 1 |
| Tatlı, B | 1 |
| Aydınlı, N | 1 |
| Özmen, M | 1 |
| Jackson, M | 1 |
| Manganaro, S | 1 |
| Fernández, IS | 1 |
| Hawkins, NA | 1 |
| Zachwieja, NJ | 1 |
| Miller, AR | 1 |
| Anderson, LL | 1 |
| Kearney, JA | 1 |
| Ertam, I | 1 |
| Sezgin, AO | 1 |
| Unal, I | 1 |
| Trojnar, MK | 1 |
| Ratnaraj, N | 1 |
| Patsalos, PN | 1 |
| Czuczwar, SJ | 1 |
| Florence, K | 1 |
| Manisha, L | 1 |
| Kumar, BA | 1 |
| Ankur, K | 1 |
| Kumar, MA | 1 |
| Ambikanandan, M | 1 |
| Cao, D | 1 |
| Ohtani, H | 1 |
| Ogiwara, I | 1 |
| Ohtani, S | 1 |
| Takahashi, Y | 1 |
| Yamakawa, K | 1 |
| Inoue, Y | 1 |
| Veggiotti, P | 1 |
| Termine, C | 1 |
| Granocchio, E | 1 |
| Bova, S | 1 |
| Papalia, G | 1 |
| Lanzi, G | 1 |
| Goldsmith, J | 1 |
| McKnight, C | 1 |
| Dickson, S | 1 |
| Heenan, M | 1 |
| Berezowski, R | 1 |
| Marsden, D | 1 |
| Libretto, SE | 1 |
| Kaushal, S | 1 |
| Rani, A | 1 |
| Chopra, SC | 1 |
| Singh, G | 1 |
| Kulkarni, S | 1 |
| Hegde, A | 1 |
| Shah, KN | 1 |
| Haigh, JR | 1 |
| Gent, JP | 1 |
| Calvert, R | 1 |
| Shenoy, AK | 1 |
| Miyahara, JT | 1 |
| Swinyard, EA | 1 |
| Kupferberg, HJ | 1 |
| Aguglia, U | 1 |
| Tinuper, P | 1 |
| Schwarer, AP | 1 |
| Opat, SS | 1 |
| Watson, AL | 1 |
| Cole-Sinclair, MF | 1 |
| Caramaschi, P | 1 |
| Biasi, D | 1 |
| Carletto, A | 1 |
| Manzo, T | 1 |
| Bambara, LM | 1 |
| Chimirri, A | 1 |
| Gitto, R | 1 |
| Grasso, S | 1 |
| Zappalà, M | 1 |
| De Sarro, A | 1 |
| Battista De Sarro, G | 1 |
| Löscher, W | 1 |
| Rundfeldt, C | 1 |
| Hönack, D | 1 |
| Ebert, U | 1 |
| Haugvicová, R | 1 |
| Kubová, H | 1 |
| Mares, P | 1 |
| Nakajima, H | 1 |
| Terra, VC | 1 |
| Garcia-Cairasco, N | 1 |
| Wildin, JD | 1 |
| Pleuvry, BJ | 1 |
| Tietz, EI | 1 |
| Bétremieux, P | 1 |
| Durand, C | 1 |
| Lefrançois, C | 1 |
| Roussey, M | 1 |
| Breurec, JY | 1 |
| Dabadie, A | 1 |
| Zifkin, B | 1 |
| Sherwin, A | 2 |
| Andermann, F | 1 |
| Kassahun, K | 1 |
| Farrell, K | 1 |
| Zheng, JJ | 1 |
| Abbott, F | 1 |
| Guberman, A | 1 |
| Couture, M | 1 |
| Blaschuk, K | 1 |
| Kruse, HJ | 2 |
| Kuch, H | 2 |
| Munn, R | 1 |
| Camfield, P | 1 |
| Camfield, C | 1 |
| Dooley, J | 1 |
| Scott, DF | 1 |
| Moffett, A | 1 |
12 reviews available for clobazam and Absence Seizure
| Article | Year |
|---|---|
Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Humans; Lennox Gastaut Syndrome; Network Meta-Analysis; Rand | 2022 |
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Topics: Adult; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug Resistant Epilepsy; Epilepsies, Myoclonic | 2023 |
Stiripentol for the treatment of seizures associated with Dravet syndrome in patients 6 months and older and taking clobazam.
Topics: Anticonvulsants; Child; Child, Preschool; Clobazam; Epilepsies, Myoclonic; Humans; Observational Stu | 2023 |
Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Drug Therapy, Combination; Epilepsies, Myoclonic; Humans; Le | 2020 |
Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Drug Interactions; Drug Therapy, Combination; Epilepsies, My | 2020 |
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Drug Therapy, Combination; Epilepsies, Myoclonic; Humans; Le | 2020 |
Clobazam monotherapy for focal or generalized seizures.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsies, Par | 2018 |
Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: A multicenter cohort study from Germany and review of literature.
Topics: Anticonvulsants; Clobazam; Cohort Studies; Drug Prescriptions; Drug Therapy, Combination; Epilepsies | 2019 |
An evaluation of clobazam tablets and film (AQST-120) for the treatment of Lennox-Gastaut syndrome.
Topics: Anticonvulsants; Clobazam; Drug Tolerance; Humans; Lennox Gastaut Syndrome; Randomized Controlled Tr | 2019 |
Clobazam monotherapy for partial-onset or generalized-onset seizures.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Clobazam; Epilepsies, Par | 2014 |
Clinical use of drugs useful in the treatment of atonic seizures.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy, Genera | 1995 |
[A pharmacological profile of clobazam (Mystan), a new antiepileptic drug].
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clinical Trials as Topic; Clobazam; | 2001 |
7 trials available for clobazam and Absence Seizure
| Article | Year |
|---|---|
Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Drug Resistant E | 2023 |
Evaluation of diazepam nasal spray in patients with epilepsy concomitantly using maintenance benzodiazepines: An interim subgroup analysis from a phase 3, long-term, open-label safety study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Diazepam; Dru | 2021 |
Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Female; Huma | 2014 |
Long-term neuropsychological follow-up and nosological considerations in five patients with continuous spikes and waves during slow sleep.
Topics: Adrenocorticotropic Hormone; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Child, Pr | 2002 |
Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Double-Blind | 2006 |
Clobazam for seizure prophylaxis during busulfan chemotherapy.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Antineoplastic Agents, Alkylating; Benzodiazepines; B | 1995 |
Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations.
Topics: Adult; Aged; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Dos | 1990 |
65 other studies available for clobazam and Absence Seizure
| Article | Year |
|---|---|
Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Benzamides; Chemical and Drug Induced Liver | 2005 |
Novel limonene and citral based 2,5-disubstituted-1,3,4-oxadiazoles: a natural product coupled approach to semicarbazones for antiepileptic activity.
Topics: Acyclic Monoterpenes; Animals; Anticonvulsants; Binding Sites; Cyclohexenes; Disease Models, Animal; | 2013 |
Design, synthesis and anticonvulsant evaluation of N-(benzo[d]thiazol-2-ylcarbamoyl)-2-methyl-4-oxoquinazoline-3(4H)-carbothioamide derivatives: a hybrid pharmacophore approach.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Disease Models, | 2013 |
Evaluation of one-year effectiveness of clobazam as an add-on therapy to anticonvulsant monotherapy in participants with epilepsy having uncontrolled seizure episodes: An Indian experience.
Topics: Adult; Anticonvulsants; Benzodiazepines; Clobazam; Epilepsy; Humans; Male; Prospective Studies; Seiz | 2022 |
The effectiveness and tolerability of clobazam in the pediatric population: Adjunctive therapy and monotherapy in a large-cohort multicenter study.
Topics: Anticonvulsants; Child; Clobazam; Cohort Studies; Epilepsy; Humans; Retrospective Studies; Seizures; | 2022 |
Pharmacotherapeutic management of seizures in patients with Angleman Syndrome.
Topics: Anticonvulsants; Cannabidiol; Child; Clobazam; Clonazepam; Ethosuximide; Humans; Lamotrigine; Leveti | 2022 |
Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach.
Topics: Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Epilepsy; Levetiracetam; Male; M | 2022 |
A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam.
Topics: Adult; Anticonvulsants; Carbamates; Clobazam; Humans; Retrospective Studies; Seizures | 2023 |
Real-world data on cannabidiol treatment of various epilepsy subtypes: A retrospective, multicenter study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug-Related Side Effects an | 2023 |
Tolerability of clobazam as add-on therapy in patients aged 50 years and older with drug-resistant epilepsy.
Topics: Aged; Anticonvulsants; Benzodiazepines; Clobazam; Drug Resistant Epilepsy; Drug Therapy, Combination | 2023 |
Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Topics: Adolescent; Anticonvulsants; Cannabidiol; Clobazam; Epilepsies, Myoclonic; Humans; Lennox Gastaut Sy | 2023 |
Pharmacokinetics of cenobamate as monotherapy compared with adjunctive therapy.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Humans; Seizures | 2023 |
Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies.
Topics: Clobazam; Drug Resistant Epilepsy; Epilepsy; gamma-Aminobutyric Acid; Humans; Precision Medicine; Pr | 2023 |
Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography.
Topics: Biomarkers; Clobazam; Deep Brain Stimulation; Drug Resistant Epilepsy; Electrocorticography; Epileps | 2023 |
Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Humans; Lennox Gastaut Syndrome; Seizures | 2020 |
Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
Topics: Adolescent; Adult; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Drug Resistant E | 2020 |
Re: Efficacy of Cannabidiol in Subjects with Refractory Epilepsy Relative to Concomitant Use of Clobazam.
Topics: Anticonvulsants; Benzodiazepines; Cannabidiol; Clobazam; Drug Resistant Epilepsy; Humans; Seizures | 2022 |
Efficacy of clobazam as add-on therapy in brain tumor-related epilepsy.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Clobazam; Drug Therapy, Combination; Epilepsy; Female | 2021 |
CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clobazam; Drug Therapy, Combination; Epilepsie | 2022 |
The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
Topics: Adolescent; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Dose-Response Relations | 2021 |
Optimizing clobazam treatment in patients with Lennox-Gastaut syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Child; Clobazam; Diagnostic Tests, Routine; Female; Humans; Lenn | 2018 |
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Topics: Adolescent; Anticonvulsants; Attention; Cannabidiol; Cannabis; Child; Child, Preschool; Clobazam; Dr | 2018 |
A survey of antiepileptic drug responses identifies drugs with potential efficacy for seizure control in Wolf-Hirschhorn syndrome.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clobazam; Female; Humans | 2018 |
Perampanel chronic treatment does not induce tolerance and decreases tolerance to clobazam in genetically epilepsy prone rats.
Topics: Acoustic Stimulation; Administration, Oral; Animals; Anticonvulsants; Brain; Clobazam; Dose-Response | 2018 |
Short burst Clobazam dosing at discharge from VEEG evaluation reduces re-presentation with seizures.
Topics: Adult; Anticonvulsants; Clobazam; Electroencephalography; Epilepsy; Humans; Patient Discharge; Retro | 2019 |
Evaluation of the Effects of Clobazam on Seizure Control and Quality of Life in Children With Lennox-Gastaut Syndrome: A Pilot Study.
Topics: Anticonvulsants; Child; Child, Preschool; Clobazam; Female; Humans; Lennox Gastaut Syndrome; Male; P | 2019 |
Safety and Efficacy of Supratherapeutic Doses of Clobazam.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clobazam; Dose-Response Relationship, Drug; Fe | 2019 |
Ictal bradycardia and asystole in an adult with a focal left insular lesion.
Topics: Anticonvulsants; Benzodiazepines; Bradycardia; Brain Diseases; Cerebral Cortex; Clobazam; Drug Resis | 2013 |
Stiripentol in Dravet syndrome: results of a retrospective U.S. study.
Topics: Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Dioxolanes; Drug Therapy, Combi | 2013 |
Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α₂- versus α₁-GABA(A)-receptor complexes.
Topics: Allosteric Site; Animals; Anticonvulsants; Benzodiazepines; Binding Sites; Brain; Clobazam; Clonazep | 2014 |
Neck myoclonia with absence seizures in an Indian girl.
Topics: Anticonvulsants; Benzodiazepines; Brain; Child; Clobazam; Electroencephalography; Epilepsies, Myoclo | 2014 |
Clobazam: effect on frequency of seizures and safety profile in different subgroups of children with epilepsy.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clobazam; Dose-Response Relat | 2014 |
Additive interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and clobazam in the mouse maximal electroshock-induced tonic seizure model--an isobolographic analysis for parallel dose-response relationship curves.
Topics: Animals; Anticonvulsants; Benzodiazepines; Clobazam; Disease Models, Animal; Dose-Response Relations | 2014 |
Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Clinical Trials, Phase | 2014 |
Influence of WIN 55,212-2 on the anticonvulsant and acute neurotoxic potential of clobazam and lacosamide in the maximal electroshock-induced seizure model and chimney test in mice.
Topics: Acetamides; Animals; Anticonvulsants; Benzodiazepines; Benzoxazines; Clobazam; Disease Models, Anima | 2014 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Bromides; Child; Child, Preschool; Clobazam; Diet, Ket | 2015 |
Influence of arachidonyl-2'-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the anticonvulsant and acute side-effect potentials of clobazam, lacosamide, and pregabalin in the maximal electroshock-induced seizure model and chimney test i
Topics: Acetamides; Animals; Anticonvulsants; Arachidonic Acids; Ataxia; Benzodiazepines; Brain; Clobazam; D | 2015 |
Aggravation of atonic seizures by rufinamide: A case report.
Topics: Anticonvulsants; Benzodiazepines; Brain; Child; Clobazam; Drug Resistant Epilepsy; Drug Therapy, Com | 2016 |
Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsy.
Topics: Anticonvulsants; Benzodiazepines; Case-Control Studies; Child; Child, Preschool; Clobazam; Drug Chro | 2016 |
Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq.
Topics: Animals; Benzodiazepines; Chromosome Mapping; Chromosomes; Clobazam; Disease Models, Animal; Epileps | 2016 |
A case with Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine, and valproic acid treatment.
Topics: Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Drug Therapy, Combination; Follow-Up S | 2009 |
Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model.
Topics: Analysis of Variance; Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Benzodiazepine | 2010 |
Intranasal clobazam delivery in the treatment of status epilepticus.
Topics: Administration, Intranasal; Animals; Anticonvulsants; Benzodiazepines; Brain; Clobazam; Drug Stabili | 2011 |
Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome.
Topics: Age Factors; Animals; Anticonvulsants; Benzodiazepines; Clobazam; Dioxolanes; Disease Models, Animal | 2012 |
Miconazole and clobazam; a useful interaction in Dravet's syndrome?
Topics: Anticonvulsants; Benzodiazepines; Child; Clobazam; Drug Interactions; Drug Therapy, Combination; Fem | 2004 |
Hypersensitivity to topiramate sprinkle capsules does not preclude the use of topiramate tablets.
Topics: Administration, Oral; Adolescent; Anticonvulsants; Benzodiazepines; Capsules; Carbamazepine; Clobaza | 2004 |
Hemifacial seizures and cerebellar tumor: a rare co-existence.
Topics: Anticonvulsants; Benzodiazepines; Cerebellar Neoplasms; Child, Preschool; Clobazam; Comorbidity; Gan | 2007 |
Plasma concentrations of clobazam and its N-desmethyl metabolite; protection against pentetrazol-induced convulsions in mice.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Injecti | 1984 |
Comparative anticonvulsant activity and neurotoxicity of clobazam, diazepam, phenobarbital, and valproate in mice and rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Diazepa | 1982 |
Eating seizures.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; | 1983 |
Clobazam-induced systemic lupus erythematosus.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Clobazam; Female; H | 1995 |
Structure-activity relationships in thienodiazepine and benzodiazepine derivatives.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Azepines; Benzodiazepines; Benz | 1994 |
Long-term studies on anticonvulsant tolerance and withdrawal characteristics of benzodiazepine receptor ligands in different seizure models in mice. I. Comparison of diazepam, clonazepam, clobazam and abecarnil.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbolines; Cloba | 1996 |
Antipentylenetetrazol action of clobazam in developing rats.
Topics: Age Factors; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Brain; Clobazam; Convul | 1999 |
Neuroethological evaluation of audiogenic seizures and audiogenic-like seizures induced by microinjection of bicuculline into the inferior colliculus. II. Effects of nigral clobazam microinjections.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Arousal; Behavior, Animal; Benz | 1992 |
Tolerance to the anticonvulsant effects of clobazam in mice.
Topics: Acoustic Stimulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepino | 1992 |
Repeated anticonvulsant testing: contingent tolerance to diazepam and clobazam in kindled rats.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Diazepa | 1992 |
[Maprotiline poisoning in an eleven-month-old infant].
Topics: Anthracenes; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Bundle-Branch Block; Clobazam; | 1990 |
Phenytoin toxicity due to interaction with clobazam.
Topics: Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Chromatography, Hig | 1991 |
Metabolic profiling of valproic acid in patients using negative-ion chemical ionization gas chromatography-mass spectrometry.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Carbamazepine; Child; Ch | 1990 |
Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Electro | 1985 |
Potentiation of clobazam's anticonvulsant activity by etifoxine, a non-benzodiazepine tranquilizer, in mice. Comparison studies with sodium valproate.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Drug Sy | 1986 |
Clobazam for refractory childhood seizure disorders--a valuable supplementary drug.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Child; Child, Preschool; | 1988 |
On the anticonvulsant and psychotropic properties of clobazam--a preliminary study.
Topics: Adult; Anti-Anxiety Agents; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy; Female; Humans; | 1986 |